EA200970911A1 - Хинолины и их терапевтическое применение - Google Patents

Хинолины и их терапевтическое применение

Info

Publication number
EA200970911A1
EA200970911A1 EA200970911A EA200970911A EA200970911A1 EA 200970911 A1 EA200970911 A1 EA 200970911A1 EA 200970911 A EA200970911 A EA 200970911A EA 200970911 A EA200970911 A EA 200970911A EA 200970911 A1 EA200970911 A1 EA 200970911A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hydrogen
quinolines
halogen
therapeutic application
optionally substituted
Prior art date
Application number
EA200970911A
Other languages
English (en)
Other versions
EA017093B1 (ru
Inventor
Джон Гари Монтана
Харри Финч
Джордж Хайнд
Майкл Колин Крамп
Роза Ариэнцо
Невилль Маклеан
Original Assignee
Арджента Орал Терапьютикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706636A external-priority patent/GB0706636D0/en
Priority claimed from GB0724430A external-priority patent/GB0724430D0/en
Application filed by Арджента Орал Терапьютикс Лимитед filed Critical Арджента Орал Терапьютикс Лимитед
Publication of EA200970911A1 publication Critical patent/EA200970911A1/ru
Publication of EA017093B1 publication Critical patent/EA017093B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Соединения формулы (I)где Rпредставляет собой атом галогена или циано; Rпредставляет собой атом водорода или метил; Rи Rнезависимо представляют собой -OR, C-Салкил или С-Сциклоалкил, причем последние две группы возможно замещены одним или более чем одним атомом галогена; Rпредставляет собой атом водорода или атом галогена; Rпредставляет собой C-Салкил или С-Сциклоалкил, каждый из которых возможно замещен одним или более чем одним атомом галогена; Х представляет собой -CH-, -S- или -О-; один из Y и Yпредставляет собой атом водорода, а другой представляет собой OR, -C(=O)R, NRSORили гетероциклическую группу, выбранную из списка, приведенного в описании изобретения; и R, Rи Rявляются такими, как определено в описании изобретения; являются лигандами CRTH2, полезными в лечении, например, астмы и ХОЗЛ.
EA200970911A 2007-04-04 2008-04-03 Хинолины и их терапевтическое применение EA017093B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0706636A GB0706636D0 (en) 2007-04-04 2007-04-04 Receptor ligands
GB0724430A GB0724430D0 (en) 2007-12-14 2007-12-14 Receptor ligands
PCT/GB2008/001201 WO2008122784A1 (en) 2007-04-04 2008-04-03 Quinolines and their therapeutic use

Publications (2)

Publication Number Publication Date
EA200970911A1 true EA200970911A1 (ru) 2010-04-30
EA017093B1 EA017093B1 (ru) 2012-09-28

Family

ID=39561800

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970911A EA017093B1 (ru) 2007-04-04 2008-04-03 Хинолины и их терапевтическое применение

Country Status (22)

Country Link
US (2) US8173812B2 (ru)
EP (1) EP2139881B1 (ru)
JP (1) JP5187862B2 (ru)
CN (1) CN101679359B (ru)
AT (1) ATE532780T1 (ru)
AU (1) AU2008235282B2 (ru)
BR (1) BRPI0809983A2 (ru)
CA (1) CA2680682C (ru)
CY (1) CY1112679T1 (ru)
DK (1) DK2139881T3 (ru)
EA (1) EA017093B1 (ru)
ES (1) ES2375588T3 (ru)
HK (1) HK1142604A1 (ru)
HR (1) HRP20110987T1 (ru)
IL (1) IL201013A (ru)
MX (1) MX2009010461A (ru)
NZ (1) NZ579659A (ru)
PL (1) PL2139881T3 (ru)
PT (1) PT2139881E (ru)
SI (1) SI2139881T1 (ru)
WO (1) WO2008122784A1 (ru)
ZA (1) ZA200906384B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2139881T3 (da) * 2007-04-04 2012-01-30 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
KR101920090B1 (ko) * 2010-07-05 2018-11-19 이도르시아 파마슈티컬스 리미티드 1-페닐-치환된 헤테로시클릴 유도체 및 프로스타글란딘 ｄ２ 수용체 조절자로서 이의 용도
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CA2858328A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
JP6256467B2 (ja) * 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
WO2015124703A1 (en) * 2014-02-24 2015-08-27 Ventana Medical Systems, Inc. Quinone methide analog signal amplification
WO2022175829A1 (en) * 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58225065A (ja) * 1982-06-21 1983-12-27 Nippon Shinyaku Co Ltd ２−キノロン誘導体
TW297025B (ru) * 1992-02-14 1997-02-01 Squibb & Sons Inc
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
AU2006296397B2 (en) * 2005-09-30 2011-12-15 Gb001, Inc. Quinolines and their therapeutic use
DK2139881T3 (da) * 2007-04-04 2012-01-30 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse

Also Published As

Publication number Publication date
CA2680682A1 (en) 2008-10-16
SI2139881T1 (sl) 2012-05-31
IL201013A (en) 2015-01-29
HRP20110987T1 (hr) 2012-01-31
CY1112679T1 (el) 2016-02-10
NZ579659A (en) 2012-01-12
JP5187862B2 (ja) 2013-04-24
EP2139881A1 (en) 2010-01-06
US20120184579A1 (en) 2012-07-19
AU2008235282B2 (en) 2011-02-24
AU2008235282A1 (en) 2008-10-16
PT2139881E (pt) 2012-01-17
JP2010523537A (ja) 2010-07-15
US8394830B2 (en) 2013-03-12
CN101679359A (zh) 2010-03-24
US8173812B2 (en) 2012-05-08
CA2680682C (en) 2015-05-26
EP2139881B1 (en) 2011-11-09
EA017093B1 (ru) 2012-09-28
ZA200906384B (en) 2010-11-24
US20100144787A1 (en) 2010-06-10
MX2009010461A (es) 2010-02-18
IL201013A0 (en) 2010-05-17
HK1142604A1 (en) 2010-12-10
BRPI0809983A2 (pt) 2014-10-14
CN101679359B (zh) 2013-03-06
ATE532780T1 (de) 2011-11-15
WO2008122784A1 (en) 2008-10-16
ES2375588T3 (es) 2012-03-02
AU2008235282A8 (en) 2009-11-26
DK2139881T3 (da) 2012-01-30
PL2139881T3 (pl) 2012-04-30

Similar Documents

Publication Publication Date Title
EA200970911A1 (ru) Хинолины и их терапевтическое применение
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
EA201101566A1 (ru) Производные имидазола и их применение в качестве модуляторов циклинзависимых киназ
EA200702363A1 (ru) Новые лиганды гистамина h-рецептора и их терапевтические применения
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
PE20140975A1 (es) Derivados de imidazopirazina como inhibidores de syk
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
EA201290260A1 (ru) Бензимидазол-имидазольные производные
PE20100138A1 (es) Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k
EA201070422A1 (ru) Производные оксадиазола
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
ATE538099T1 (de) 2-ä1-phenyl-5-hydroxy-4-alpha-methyl- hexahydrocyclopentaäfüindazol-5- ylüethylphenylderivate als glucocorticoidrezeptorliganden
EA201001683A1 (ru) Производные фенил- или пиридинилзамещенных индазолов
EA201001273A1 (ru) Ингибиторы вируса гепатита с
EA201291236A1 (ru) Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
EA201171328A1 (ru) Производное замещенного изохинолина
EA201290073A1 (ru) Соединения мочевины, содержащие 5,6-бициклический гетероарил, как ингибиторы киназ
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
EA201170153A1 (ru) Микроциклические производные индола, пригодные в качестве ингибиторов вируса гепатита с
MX2009009384A (es) Malonamidas como antagonistas de orexina.
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
AR072809A1 (es) Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende
MY153042A (en) Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU